Savara (SVRA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SVRA Savara

Watchlist

3.240
+0.110+3.51%

Close Nov 21 16:00 ET

3.200
-0.040-1.23%

Post 19:06 ET

556.05MMarket Cap-7534P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Independent Director of Savara David Ramsay Buys 4.5% More Shares
Simply Wall StNov 21 05:06 ET
Insider Purchase: Director at $SVRA (SVRA) Buys 20,000 Shares
Quiver QuantitativeNov 20 08:00 ET
Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing
MT NewswiresNov 18 12:37 ET
Savara Is Maintained at Buy by HC Wainwright & Co.
Dow JonesNov 13 09:53 ET · Ratings
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $15
Moomoo NewsNov 13 08:36 ET · Ratings
Oppenheimer Keeps Their Buy Rating on Savara (SVRA)
TipRanksNov 13 08:08 ET · Ratings

Comments

Teddy123

Nov 12 07:26

In the pipeline

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...

NEWS

$Savara (SVRA.US)$
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapn...